OSI, Pfizer cancer news

OSI said the U.S. Patent and Trademark Office issued to Pfizer and the biotech U.S. Patent No. RE41,065 covering the composition of matter for Tarceva erlotinib. The reissued patent replaces U.S. Patent No. 5,747,498 and corrects errors relating to other compounds claimed in the original patent. The '065 patent has the same Nov. 18, 2018, expiration date as the original. ...